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Diabetic nephropathy is a major complication in type 2 diabe-
tes mellitus and a leading cause of end-stage renal failure.1 The 
first sign of diabetic nephropathy is the appearance of albumin 
in the urine (microalbuminuria).2 Although the mechanisms 
underlying the occurrence of microalbuminuria in type 2 dia-
betes are extremely complex, the potential role of the renin-
angiotensin system has been suggested.3–11 Large-scale clinical 
trials have shown that in hypertensive type 2 diabetic patients 
with microalbuminuria, lowering blood pressure by blockade 
of the renin-angiotensin system with angiotensin II (Ang II) 
type 1 (AT1) receptor blockers (ARBs) or angiotensin-con-
verting enzyme inhibitors is more effective in reducing micro-
albuminuria  than  any  other  conventional  antihypertensive 
therapies.3–7 These findings suggest that the antialbuminuric 
effects of renin-angiotensin system inhibition are independent 
of their blood pressure-lowering effects.12
Recently,  the  Randomized  Olmesartan  and  Diabetes 
Microalbuminuria  Prevention  (ROADMAP)  study  was 
  conducted  to  examine  if  an  ARB  can  prevent  the  onset  of 
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Background
Studies were performed to determine if early treatment with an 
angiotensin II (ang II) receptor blocker (aRB), olmesartan, prevents 
the onset of microalbuminuria by attenuating glomerular podocyte 
injury in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with type 2 
diabetes mellitus.
Methods
OLETF rats were treated with either a vehicle, olmesartan (10 mg/kg/
day) or a combination of nonspecific vasodilators (hydralazine 15 mg/
kg/day, hydrochlorothiazide 6 mg/kg/day, and reserpine 0.3 mg/kg/
day; HHR) from the age of 7–25 weeks.
results
OLETF rats were hypertensive and had microalbuminuria from 
9 weeks of age. at 15 weeks, OLETF rats had higher ang II levels 
in the kidney, larger glomerular desmin-staining areas (an index 
of podocyte injury), and lower gene expression of nephrin in 
juxtamedullary glomeruli, than nondiabetic Long-Evans Tokushima 
Otsuka (LETO) rats. at 25 weeks, OLETF rats showed overt 
albuminuria, and higher levels of ang II in the kidney and larger 
glomerular desmin-staining areas in superficial and juxtamedullary 
glomeruli compared to LETO rats. Reductions in mRNa levels of 
nephrin were also observed in superficial and juxtamedullary 
glomeruli. although olmesartan did not affect glucose metabolism, it 
decreased blood pressure and prevented the renal changes in OLETF 
rats. HHR treatment also reduced blood pressure, but did not affect 
the renal parameters.
conclusions
This study demonstrated that podocyte injury occurs in 
juxtamedullary glomeruli prior to superficial glomeruli in type 2 
diabetic rats with microalbuminuria. Early treatment with an aRB 
may prevent the onset of albuminuria through its protective effects 
on juxtamedullary glomerular podocytes.
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microalbuminuria.13  It  has  been  demonstrated  that  early 
treatment  with  the  ARB,  olmesartan,  significantly  reduced 
the  occurrence  rate  of  microalbuminuria  in  type  2  diabe-
tes  patients.14  However,  the  precise  mechanisms  by  which 
intensive Ang II blockade during a prediabetic state prevents 
the  occurrence  of  microalbuminuria  are  not  completely 
understood.
A growing body of evidence has indicated that one of the 
most important mechanisms in the development of albuminu-
ria  is  injury  to  glomerular  epithelial  cells  (podocytes).15–17 
Therefore, we hypothesized that the beneficial effect of an ARB 
on the onset of microalbuminuria is associated with its protec-
tive effect on podocyte injury. In particular, we aimed to char-
acterize the mechanisms by which microalbuminuria develops 
in early type 2 diabetic nephropathy by focusing on the het-
erogeneity  of  glomerular  podocyte  abnormalities  in  type  2 
diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats, 
which exhibit pathological features of renal injury similar to 
those found in human type 2 diabetic patients with hyperten-
sion, obesity, and hyperinsulinemia.10,11,18–20
Methods
Experimental  procedures  were  conducted  according  to  the 
guidelines  for  the  care  and  use  of  animals  established  by 
Kagawa University (Kagawa, Japan).
Animals.  Eighty-two  male  5-week-old  OLETF  rats  and  30 
male  age-matched  Long-Evans  Tokushima  Otsuka  (LETO) 
rats (genetic control for OLETF rats) were supplied by Otsuka 
Pharmaceutical (Tokushima, Japan).
After measuring physical and laboratory data at baseline, 
each five LETO and OLETF rats were killed at 5 and 7 weeks 
of  age,  respectively.  The  remaining  OLETF  rats  were  then 
randomly treated with one of the following foods:   standard 
diet (n = 20); olmesartan (0.02% in chow, 10–15 mg/kg/day; 
Daiichi-Sankyo, Tokyo, Japan): (n = 24); HHR (hydralazine 
0.03%,  hydrochlorothiazide  0.012%,  reserpine  0.006%  in 
chow; Sigma Chemical, St. Louis, MO, for each): (n = 24). The 
remaining LETO rats (n = 20) were fed a standard diet. The 
doses of olmesartan and HHR were determined on the basis of 
previous studies on rats.10,21 At 15 weeks of age, 2 OLETF rats 
and 10 LETO rats treated with standard diet and 12 OLETF 
rats treated with olmesartan and HHR were killed. The remain-
ing rats continued to receive their treatment until 25 weeks of 
age (12 OLETF rats and 12 LETO rats with a standard diet, 
and 12 OLETF rats with olmesartan and 12 OLETF rats HHR). 
Systolic blood pressure (SBP) was measured in conscious rats 
by tail-cuff plethysmography (BP-98A; Softron, Tokyo, Japan). 
Detailed  methods  for  sample  preparation  and  histological 
analyses are available in the Supplementary Methods online.
Real-time  reverse  transcription-polymerase  chain  reaction 
(RT-PCR). The regions of superficial glomeruli and juxtamedul-
lary glomeruli in renal cortex tissues were separated and dis-
sected by a laser capture microdissection system. RT-PCR for 
nephrin, podocin, and 18s was done after mRNA   isolation from 
laser capture microdissection samples. The mRNA expression 
levels  of  endothelial  nitric  oxide  synthase  (eNOS),  vascular 
endothelial growth factor (VEGF), and VEGF receptor 1 and 2 
(VEGFR1 and VEGFR2) in renal cortical tissues were measured 
by RT-PCR. Data for mRNA levels were expressed as the rela-
tive differences between OLETF rats and LETO rats after nor-
malization of 18s expression. All information relating to mRNA 
primers is available in the Supplementary Methods online.
Other analytical procedures. Detailed information regarding 
other analytical procedures is available in the Supplementary 
Methods online.
Statistical analyses. Values are means ± s.e.m. Statistical com-
parisons of differences were carried out using one-way or two-
way ANOVA combined with the Newman–Keuls post-hoc test. 
P < 0.05 was considered significant.
results
sBP, body weight, kidney weight, visceral fat weight, and 
blood glucose
The serial profiles of SBP are shown in Figure 1a. At 5 and 
7 weeks of age, each group of OLETF rats showed similar SBP. 
During  the  observation  period,  vehicle-treated  OLETF  rats 
progressively  developed  hypertension.  OLETF  rats  treated 
with olmesartan or HHR resulted in similar reductions in SBP. 
Kidney weight and visceral fat weight per body weight ratios 
were higher in OLETF rats than in LETO rats. The serial pro-
files of body weight, postprandial blood glucose, and kidney 
weight and visceral fat weight per body weight are available in 
the Supplementary Figure S1a and Supplementary Table S1 
online.
urinary excretion rate of albumin (ualbV) and urinary protein 
excretion
The profiles of UalbV are shown in Figure 1b. At 5 and 7 weeks 
of age, UalbV between untreated LETO and OLETF rats was 
similar, and calculated UalbV values did not significantly differ 
between these rats. At 9 weeks of age, vehicle-treated OLETF 
rats  showed  microalbuminuria  (1.0  ±  0.2 mg/day),  whereas 
LETO rats did not (0.2 ± 0.02 mg/day). After 9 weeks of age, 
UalbV of vehicle-treated OLETF rats progressively increased 
with age and resulted in massive proteinuria at 25 weeks of 
age. Treatment with olmesartan prevented the onset of micro-
albuminuria (>1.0 mg/day) in OLETF rats until 25 weeks of 
age (0.44 ± 0.1 mg/day at 25 weeks of age). Treatment with 
HHR also attenuated the progression of UalbV in OLETF rats. 
However, the effects of HHR on UalbV were much less than 
those of olmesartan (21.5 ± 2.0 mg/day at 25 weeks of age). The 
serial profiles of urinary protein excretion are available in the 
Supplementary Figure S1b online.
Plasma triglyceride, glycated albumin, insulin, adiponectin, 
and creatinine levels
OLETF rats showed higher plasma triglyceride, insulin, and 
glycated albumin levels than that of LETO rats at 25 weeks of 606     May 2012 | VOLUME 25 NUMBER 5 | AMERICAN JOURNAL OF HYPERTENSION
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age. Treatment with olmesartan decreased plasma triglyceride 
level, but did not decrease plasma insulin and glycated albu-
min levels. Plasma adiponectin levels were similar between 
olmesartan-treated  rats  and  vehicle-treated  rats  in  OLETF 
rats at 25 weeks of age. At 15 and 25 weeks of age, no signifi-
cant difference in creatinine level was observed in OLETF rats 
given any antihypertensive treatment. Detailed data are avail-
able in the Supplementary Table S1 online.
histological findings
At  15  and  25  weeks  of  age,  vehicle-treated  LETO  rats  and 
OLETF rats showed no obvious glomerular sclerosis in PAS-
staining areas. Glomerular size was not significantly different 
among the groups at 15 weeks of age. At 25 weeks of age, the 
size of superficial glomeruli in OLETF rats was larger than 
those in LETO rats. Juxtamedullary glomeruli tended to be 
larger  than  superficial  glomeruli  in  OLETF  rats,  but  these 
changes  were  not  statistically  significant.  Detailed  data  for 
PAS-staining areas and glomerular sizes are available in the 
Supplementary Figure S2 online.
The glomerular histological findings for the immunostain-
ing of desmin in superficial and juxtamedullary glomeruli are 
shown in Figure 2a,b, respectively. At 5 and 7 weeks of age, 
there was no significant difference in the desmin-staining area 
between vehicle-treated LETO rats and OLETF rats (data not 
shown). However, at 15 weeks of age, the glomerular desmin-
positive area was significantly larger in vehicle-treated OLETF 
rats than in LETO rats in only juxtamedullary glomeruli, but not 
in superficial glomeruli. Afterwards, the glomerular desmin-
positive area became larger in vehicle-treated OLETF rats than 
in LETO rats in juxtamedullary and superficial glomeruli at 25 
weeks of age. In OLETF rats, treatment with olmesartan pre-
vented enlargement of the glomerular desmin-positive area in 
juxtamedullary and superficial glomeruli to values that did not 
differ significantly from those of LETO rats until 25 weeks of 
age. Conversely, the glomerular desmin-positive area was not 
different between vehicle- and HHR-treated OLETF rats except 
in juxtamedullary glomeruli at 15 weeks of age.
At 25 weeks of age, observation of podocyte ultrastructure 
by electron microscopy revealed marked podocyte foot proc-
ess effacement in vehicle-treated OLETF rats, whereas olm-
esartan-treated  OLETF  rats  showed  a  marked  reduction  in 
podocyte foot process effacement resembling that seen in vehi-
cle-treated LETO rats. In contrast, HHR-treated OLETF rats at 
25 weeks of age did not show as much reduction in podocyte 
foot  process  effacement  as  compared  with  the  olmesartan-
treated OLETF rats (Figure 2c).
Immunofluorescence microscopy of the slit diaphragm-asso-
ciated molecules nephrin and podocin revealed loss of immu-
nostaining  continuity  in  vehicle-  and  HHR-treated  OLETF 
rats at 25 weeks of age, which showed massive albuminuria. 
Moreover, unbound nephrin and podocin were observed in a 
merged image. On the other hand, immunofluorescence conti-
nuity and the binding between nephrin and podocin were main-
tained in OLETF rats treated with olmesartan compared with 
vehicle-treated OLETF rats at 25 weeks of age (Figure 3a).
Oil red O-staining showed lipid to accumulate predominantly 
in  proximal  tubular  cells,  but  not  in  glomerulus  of  OLETF 
rats at 25 weeks of age. Treatment with olmesartan attenuated 
lipid accumulation in proximal tubular cells. Reduction in the 
CD34-staining area in glomerular capillary was not observed in 
OLETF rats at 25 weeks of age. Podocyte number, determined 
by mean WT-1+ cells per glomerular cross section, was similar 
in OLETF rats and LETO rats at 25 weeks of age. Any treatment 
did not change podocyte number. Detailed data are available in 
the Supplementary Figures S3 and S4 online.
gene expression of the slit diaphragm-associated molecules 
nephrin and podocin and endothelial markers
Figure 3b–d shows the mRNA levels of the slit diaphragm-
associated molecules nephrin and podocin in superficial and 
juxtamedullary glomeruli. At 15 weeks of age, the mRNA 
levels of nephrin and podocin in the superficial glomeruli of 
LETO and OLETF rats were similar (Figure 3b,c). However, 
in juxtamedullary glomeruli, the mRNA levels of nephrin and 
podocin were significantly lower in OLETF rats than those 
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in LETO rats at this age (Figure 3d,e). At 25 weeks of age, 
the mRNA levels of nephrin and podocin in vehicle-treated 
OLETF rats were lower than those in LETO rats in superfi-
cial and juxtamedullary glomeruli. In OLETF rats, treatment 
with olmesartan restored the levels of the gene expression of 
nephrin and podocin to the levels that did not differ from 
those in LETO rats. However, treatment with HHR did not 
alter the mRNA levels of nephrin and podocin in OLETF 
rats. At 15 and 25 weeks of age, mRNA levels of eNOS, VEGF, 
VEGFR1,  and  VEGF2  in  vehicle-treated  OLETF  rats  were 
higher than those in LETO rats. In OLETF rats, treatment 
with olmesartan or HHR mix reduced expression of these 
genes to levels similar to those in LETO rats. Detailed data 
are available in the Supplementary Figure S5 online.
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ang ii content in the kidney
Figure 4 shows Ang II content in the kidney. At 15 weeks of 
age, intrarenal Ang II contents were significantly higher in 
vehicle-treated OLETF rats than those in LETO rats (183 ± 
33 vs. 107 ± 10 fmol/g). Ang II levels in the kidney were 
  progressively augmented at 25 weeks of age in vehicle-treated 
OLETF rats (376 ± 27 fmol/g). Treatment with olmesartan 
prevented an increase in intrarenal Ang II levels in OLETF 
rats (26 ± 2 and 110 ± 17 fmol/g at 15 and 25 weeks of age, 
respectively). Ang II contents in the kidney did not differ 
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between vehicle- and HHR-treated OLETF rats (131 ± 13 and 
291 ± 36 fmol/g at 15 and 25 weeks of age, respectively).
glomerular dhe staining
DHE staining in glomeruli was significantly higher in vehi-
cle-treated OLETF rats than in LETO rats at 15 and 25 weeks 
of age. Treatment with olmesartan prevented the increase in 
DHE staining in glomeruli until 25 weeks of age. Detailed data 
are available in the Supplementary Table S2 online.
discussion
The present study demonstrated that podocyte injury occurs in 
juxtamedullary glomeruli prior to superficial glomeruli in type 2 
diabetic OLETF rats with microalbuminuria. These data indicate, 
for the first time, that the initiation of   microalbuminuria is accom-
panied by juxtamedullary glomerular podocyte injury in type 2 
diabetes. We also showed that early treatment with olmesartan 
(an ARB) could prevent the occurrence of microalbuminuria in 
OLETF rats, as was recently demonstrated by the ROADMAP 
study in type 2 diabetic patients with normoalbuminuria.14 Our 
data also indicate that these effects of olmesartan were associated 
with the prevention of juxtamedullary podocyte injury.
Early morphological changes in the glomeruli are usually 
subclinical  and  asymptomatic  prior  to  the  development  of 
albuminuria.1,22 Several studies have shown that OLETF rats 
exhibit apparent glomerular sclerosis and interstitial injuries 
with maintained plasma creatinine levels after 50 weeks of 
age.10,18,19 In the present study, OLETF rats exhibited micro-
albuminuria  (>1.0 mg/day)  from  9  weeks  of  age  and  then 
progressed to overt proteinuria in an age-dependent man-
ner. Although diabetic OLETF rats had a marked increase in 
UalbV at 25 weeks of age, histological analyses failed to show 
significant  glomerular  sclerosis.  However,  a  more  careful 
assessment of the morphology with desmin immunostaining 
revealed that podocyte injury exists only in juxtamedullary 
glomeruli with the presence of microalbuminuria at 15 weeks 
of age.
Contribution  of  podocyte  functional  abnormalities  to  the 
progression of proteinuria has been indicated by recent stud-
ies.23–25 In the present study, we documented that juxtamedul-
lary glomerular podocyte injury was observed at the initiation 
of microalbuminuria in type 2 diabetic rats. Kim et al.26 found 
that the expression of nephrin, which is a functional molecule 
located between slit diaphragms or two adjacent foot processes 
of podocytes, plays a critical role in proteinuria associated with 
diabetes,23,24,27 and that nephrin expression was significantly 
reduced  in  large  glomeruli  compared  with  small  glomeruli 
in streptozotocin-induced diabetic rats. In the present study, 
nephrin and podocin were observed to exist separately in a 
merged image. We also showed that nephrin expression was 
markedly reduced in juxtamedullary glomeruli, whereas it was 
not altered in superficial glomeruli of type 2 diabetic rats with 
microalbuminuria. These data are consistent with the notion that 
the urinary albumin excretion considerably derives from jux-
tamedullary glomeruli during the early phase of albuminuria.
It has been reported that mechanical stretch induces mor-
phological  and  cytoskeletal  change  in  podocytes  in  vitro.28 
Recent reports also showed that mechanical stretch on cul-
tured podocytes stimulated Ang II production, resulting in 
a reduction of nephrin expression, but not podocyte apopto-
sis.29 These observations, combined with our findings, sug-
gest that podocyte abnormalities, such as loss of nephrin and 
podocin, occur prior to podocyte detachment, or foot process 
effacement, in the juxtamedullary glomeruli of early diabetic 
nephropathy accompanied with hypertension. While glomer-
ular size in juxtamedullary glomeruli tended to be larger than 
those in superficial glomeruli in OLETF rats at 15 weeks of age, 
these differences were not statistically significant. Because half 
of the left kidneys for paraffin embedding were perfused using 
saline, rather than formalin, it is possible that the glomerular 
size measurements lacked accuracy.
Interestingly, the present study also showed that treatment 
with  an  ARB  prevented  microalbuminuria  via  the  protec-
tion of nephrin and podocin expression, whereas treatment 
with HHR did not. Thus, the protective effect of ARBs against 
podocyte injury cannot be explained simply by its blood pres-
sure-lowering effects. Hoffmann26,30 showed that transgenic 
rats    overexpressing  the  AT1  receptor  in  podocytes  devel-
oped  proteinuria  without  changes  in  blood  pressure.  These 
data are consistent with a recent in vitro study,31 where Ang 
II directly reduced nephrin expression in cultured podocytes. 
Nevertheless, we also observed that HHR treatment had mod-
erate effects on juxtamedullary glomerular podocyte injury, 
as determined by desmin-staining, at the onset of microalbu-
minuria. These results suggest that a reduction in blood pres-
sure can, in part, attenuate glomerular damage, as suggested 
by recent clinical studies.32,33 Mori et al.11 reported that jux-
tamedullary glomerular injury is mainly induced by high renal 
perfusion pressure, whereas superficial glomeruli are directly 
injured by Ang II in Ang II-infused hypertensive rats.
Previous  studies  have  shown  that  glomerular  capillary 
endothelial  cell  proliferation  determined  by  CD34-staining 
and increases in renal eNOS and VEGF expression occurred 
Figure 4 | ang II contents in the kidney. Treatment with olmesartan prevents an 
increase in intrarenal ang II levels in OLETF rats. *P < 0.05; OLETF vs. LETO, †P  < 
0.05; OLETF + vehicle vs. OLETF + olmesartan or HHR. ang II, angiotensin II; HHR, 
hydralazine, hydrochlorothiazide, and reserpine; LETO, Long-Evans Tokushima 
Otsuka rats; OLETF, Otsuka Long-Evans Tokushima Fatty rats.
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in  diabetic  rats.34,35  In  the  present  study,  endothelial  dete-
rioration was not observed, but increased eNOS, VEGF, and 
VEGFR2 expression was observed in kidneys of 25-week-old 
OLETF rats. From these results, we speculate that eNOS and 
VEGF increase to maintain endothelial structure during the 
development  of  diabetic  nephropathy.  Furthermore,  WT-1 
analysis  revealed  that  reduced  podocyte  number  was  not 
observed, although podocyte dysfunction, such as reductions 
in nephrin and podocin, was observed in OLETF rats. These 
data suggest that podocyte dysfunction, but not podocyte loss, 
plays an important role in the onset of microalbuminuria.
ARBs reduce intrarenal Ang II levels through prevention of 
AT1 receptor-mediated uptake of Ang II and/or intrarenal pro-
duction of Ang II by overexpression of angiotensinogen.36 In 
the present study, we observed that treatment with an ARB—
olmesartan—strongly inhibits augmentation of intrarenal Ang II 
levels in OLETF rats, decreasing them to levels even lower than 
those in LETO rats. On the other hand, we previously showed 
that treatment with telmisartan, another ARB,11 and temporary 
treatment with temocapril, an angiotensin-converting enzyme 
inhibitor,10 could suppress development of both renal injury 
and augmentation of intrarenal Ang II in OLETF rats.
Previous studies have shown that olmesartan elicits benefi-
cial effects against metabolic disorder.37,38 In the present study, 
short-term treatment with olmesartan significantly decreased 
plasma triglyceride level, but did not change fat weight, glu-
cose metabolism, and plasma insulin and adiponectin levels 
in 25-week-age OLETF rats. Thus, it is possible that the reno-
protective  effect  of  olmesartan  is  not  mediated  through  its 
antimetabolic  effect  under  the  present  experimental  condi-
tions. Lipid accumulation was observed in proximal tubular 
cells, but not glomeruli, of OLETF rats.
In conclusion, the present study demonstrated, for the first 
time, that the onset of microalbuminuria is associated with 
podocyte abnormalities in the juxtamedullary glomeruli prior 
to morphological glomerular injury in type 2 diabetic rats. 
Furthermore, our data also support the observations of the 
ROADMAP studies14 and the concept that selective inhibition 
of Ang II in the early stages of type 2 diabetes could prevent 
diabetic nephropathy.
Supplementary material is linked to the online version of the paper at 
http://www.nature.com/ajh
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